Cardiology

>

Latest News

Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins | Image Credit: © 125154153 - stock.adobe.com.
Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins

June 18th 2025

Currently, omaveloxolone (Skyclarys) is approved to treat adults and adolescents aged 16 years and older impacted by FA.

FDA approves pediatric indication for Optison ultrasound enhancing agent | Image credit: Contemporary Pediatrics
FDA approves pediatric indication for Optison ultrasound enhancing agent

May 13th 2025

Full recap from the 2025 Pediatric Academic Societies meeting |  Image Credit: © SCStock - © SCStock - stock.adobe.com.
Full recap from the 2025 Pediatric Academic Societies meeting

May 1st 2025

Elamipretide to treat Barth syndrome sees FDA target action delay | Image Credit: © Araki Illustrations - © Araki Illustrations  - stock.adobe.com.
Elamipretide to treat Barth syndrome sees FDA target action delay

April 30th 2025

Quiz: AAP critical congenital heart disease screening recommendations | Image Credit: © Daqota - © Daqota - stock.adobe.com.
Quiz: AAP critical congenital heart disease screening recommendations

April 11th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.